Tarlatamab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AMG757; AMG-757 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Tarlatamab is a bispecific T cell engager that binds DLL3 and CD3 which has shown promise for previously treated small cell lung cancer.[1]
References
- ↑ Ahn, Myung-Ju; Cho, Byoung Chul; Felip, Enriqueta; Korantzis, Ippokratis; Ohashi, Kadoaki; Majem, Margarita; Juan-Vidal, Oscar; Handzhiev, Sabin; Izumi, Hiroki; Lee, Jong-Seok; Dziadziuszko, Rafal; Wolf, Jürgen; Blackhall, Fiona; Reck, Martin; Bustamante Alvarez, Jean (2023-11-30). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". New England Journal of Medicine. 389 (22): 2063–2075. doi:10.1056/NEJMoa2307980. ISSN 0028-4793.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.